The FDA clears Hookipa Pharma’s (NASDAQ:HOOK) Investigational New Drug (IND) Application for HB-202, to initiate an additional arm in its Phase 1/2 clinical trial for HB-201 for the treatment of Human Papillomavirus 16-positive (HPV 16+) cancers.
The IND clearance will not only examine safety and
efficacy of HB-201 alone but also HB-201 in combination with HB-202 as
an alternating two-vector therapy.
Hookipa expects to combine HB-202/201 with an approved checkpoint inhibitor, in 2021.
https://seekingalpha.com/news/3583709-hookipa-to-commence-additional-arm-in-hbminus-201-trial-for-hpv-cancers
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.